2. Who Sponsored This Study?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study who made denosumab, the medicine(s) still
being tested in the study. Daiichi Sankyo is the local sponsor of the study in Japan.
Amgen would like to thank everyone who participated in this study and feels it is
important to share the results of this study.
3. General Information About the Clinical Trial
Where and when was the study done?
 This study took place in France, Russian Federation, Greece, Italy, Bulgaria,
Poland, Czech Republic, Spain, Ukraine, Hungary, Turkey, United Kingdom,
Lithuania, Austria, Portugal, Switzerland, Ireland, Slovakia, Germany, United
States, Canada, Republic of Korea, Australia, Japan, Taiwan, Singapore,
Malaysia, Hong Kong, and New Zealand.
 The study began in May 2012 and ended in March 2019.
 The study was completed as planned.
Why was the study done?
Multiple myeloma is cancer that begins in the plasma cells, which are a type of white
blood cell. White blood cells are part of the body’s immune system. Patients with
multiple myeloma may have problems with their bones, such as bone lesions (spots
of bone damage), frequent broken bones, bone pain, and pressure on the spinal
cord. They may also feel very tired and have frequent infections.
Patients with multiple myeloma may need radiation therapy or surgery to treat their
bone complications. Medicines can also be prescribed to prevent bone
2